HS
PRTK

HighVista Strategies’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

HighVista Strategies’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-19,182
Closed -$93K – 134
2021
Q3 		$93K Buy
+19,182
New +$106K 0.06% 108

Other funds holding PRTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
FIG
Fortress Investment Group New York $394M AUM 22.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HighVista Strategies's PRTK Position: Q4 2021 in Review

HighVista Strategies sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q4 2021, closing a stake of 19,182 shares — an estimated $93K sold.

HighVista Strategies first reported a position in PRTK in Q3 2021 and held it in 1 quarter. The position peaked at $93K in Q3 2021. 103 funds tracked by Wall St. Rank hold PRTK as of Q4 2021.

  • HighVista Strategies reported no remaining Paratek Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
  • HighVista Strategies sold 19,182 Paratek Pharmaceuticals, Inc. shares in Q4 2021, an estimated $93K.
  • HighVista Strategies first reported a position in Paratek Pharmaceuticals, Inc. in Q3 2021 and held it in 1 quarter.
  • HighVista Strategies's Paratek Pharmaceuticals, Inc. position peaked at $93K in Q3 2021.
  • 103 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q4 2021.

Based on HighVista Strategies's 13F filing for Q4 2021, filed 14 Feb 2022.